Emmanuelle Verger

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Genetic screening of triple negative thrombocytosis patients identifies germline MPL compound mutations and SH2B3/LNK truncating mutations.

Genetic screening of triple negative thrombocytosis patients identifies germline MPL compound mutations and SH2B3/LNK truncating mutations.

Journal: Haematologica
Published: March 06, 2026

Genetic screening of triple negative thrombocytosis patients identifies germline MPL compound mutations and SH2B3/LNK truncating mutations.

Genetic screening of triple negative thrombocytosis patients identifies germline MPL compound mutations and SH2B3/LNK truncating mutations.

Journal: Haematologica
Published: March 06, 2026

A molecular signature predicts hematologic evolution in polycythemia vera patients.

A molecular signature predicts hematologic evolution in polycythemia vera patients.

Journal: Leukemia
Published: April 03, 2025

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.

Journal: Nature communications
Published: February 23, 2024

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.

Journal: American journal of hematology
Published: September 29, 2023

Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.

Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.

Journal: Blood advances
Published: September 21, 2023

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.

Journal: Leukemia
Published: September 05, 2023

Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).

Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).

Journal: Leukemia
Published: January 29, 2023

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.

Journal: Blood advances
Published: August 03, 2021

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement.

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement.

Journal: British journal of haematology
Published: June 24, 2021

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.

Journal: Blood
Published: December 14, 2020

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Journal: Blood advances
Published: September 18, 2020
Showing 1-12 of 30

Last Updated: 09/26/2026